undamentalytics Newsletter
Sign in

Atyr Pharma Inc income statement

In fiscal 2025, Atyr Pharma Inc reported revenue of $190,000, down 19.1% on the year before, operating income of −$77.6m (a -40856.3% margin) and net income of −$74.1m, or −$0.80 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue010010000
Research and development14172343425460
General and administrative991114131418
Operating income−23−16−34−46−55−68−78
Income before tax−24−16−34−45−50−64−74
Income tax0000000
Net income−16−16−34−45−50−64−74
Diluted EPS−$1.76−$0.44−$0.89−$0.80−$0.94−$0.86−$0.80
Diluted shares (average)13m37m38m57m54m74m93m
EBITDA−22−15−34−46−54−67−77

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ATYR vs CLNNATYR vs CLDXATYR vs CRVO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atyr Pharma Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atyr Pharma Inc.